- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02209467
Balance and Falls in Multiple Sclerosis
Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins
The study hypothesis is that for people with moderate to severe multiple sclerosis postural balance and walking improve and the risk of accidental falls are reduced after participating in a specific training intervention of 7 weeks. The hypothesis is also the the effect remain a further 7 weeks post training.
Multiple Sclerosis (MS) is disease affecting the central nervous system. Walking and postural balance are often affected early in the course of the disease. The risk of falls is large. Many persons with MS have decreased trunk stability compared to healthy persons . In an earlier study including people with mild to moderate MS we found that a period of core stability exercises reduced the risk of falls. In this study the training concept will be applied for persons with more severe walking limitations.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Eskilstuna, Sweden
- Neurorehab Mälarsjukhuset
-
Gävle, Sweden
- Physiotherapy department Gävle hospital
-
Karlskoga, Sweden
- Rehab unit Karlskoga hospital
-
Linköping, Sweden
- Primary Health Care
-
Nyköping, Sweden
- Nyköping Hospital
-
Västerås, Sweden
- Rehab unit Västerås hospital
-
Örebro, Sweden
- Physiotherapy department University hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosed multiple sclerosis
- Expanded Disability Scale Score of 5-6.5
- walking speed of less than 0.8 m/s as tested on a 10 meter walking test
Exclusion Criteria:
- Ongoing relapse
- Cognitive or language difficulties that prohibit participating in the intervention or performing the outcome measures
- Change in specific MS medication during the last 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Group balance training late start
Participants randomized to late start act as No intervention group during the study period.
|
|
Experimental: Group balance training early start
Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
|
Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week.
Exercises focus om core stability in sitting, standing and lying.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Berg Balance Scale at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in 10 repetitions Sit to stand test at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline in Trunk Impairment scale at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline in the Trunk Impairment Scale at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline in the 10 repetition Si to stand test at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline in the Berg Balance scale at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline on the Timed Up and Go test at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline on the Timed Up and Go test at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline on the10 meter walking test at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline on the 10 meter walking test at 15 weks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline on the 2 minutes walking test at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline on the 2 minutes walking test at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline in postural sway at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline in postural sway at 15 weeks
Time Frame: baseline, 15 weeks
|
postural sway in standing on the floor is assessed
|
baseline, 15 weeks
|
Change from baseline on the Falls-Efficacy scale at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline on the Falls Efficacy scale at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline on the Fatigue Scale for Motor and Cognitive functions at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline on the Fatigue Scale for Motor and Cognitive functions at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
Change from baseline on the MS Walking Scale-12 at 8 weeks
Time Frame: baseline, 8 weeks
|
baseline, 8 weeks
|
|
Change from baseline on the MS Walking scale-12 at 15 weeks
Time Frame: baseline, 15 weeks
|
baseline, 15 weeks
|
|
The number of falls and accidental falls
Time Frame: from baseline to 15 weeks
|
the number of falls and accidental falls are noted by the participant in a study-specific falls diary.
|
from baseline to 15 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Anette Forsberg, PhD, Family Medicine Research Centre, Örebro County Council
- Principal Investigator: Anna Carling, MSc, Centre for Health Care Sciences, Örebro County Council
- Study Director: Ylva Nilsagård, PhD, Centre for Health Care Sciences, Örebro County Council
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Researchweb 153691
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Group balance training
-
RehaClinic AGCompleted
-
Örebro County CouncilNorrbacka-Eugenia Foundation; Uppsala-Örebro Regional Research CouncilCompleted
-
Hacettepe UniversityUnknown
-
Maharishi Markendeswar University (Deemed to be...Completed
-
Riphah International UniversityCompleted
-
Oslo University HospitalNorwegian Fund for Postgraduate Training in PhysiotherapyCompletedHealth-Related Quality of LifeNorway
-
Gazi UniversityCompleted
-
University of Texas Southwestern Medical CenterCompleted
-
Nordlandssykehuset HFUniversity Hospital of North Norway; University of Tromso; Hasselt University; University... and other collaboratorsUnknown
-
Najran UniversityCompletedSacroiliac Joint DysfunctionSaudi Arabia, India